Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges

Figure 1 A schematic illustration showing how glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide act on multiple organs to mitigate metabolic dysfunction-associated steatotic liver disease. GLP-1: Glucagon-like peptide 1; GIP: Glucose-dependent insulinotropic polypeptide.